Samsung Biologics $1.8B PolyPeptide bid
Samsung Biologics’ $1.8B PolyPeptide bid reframes Asia’s CDMO race. On 19 July 2026 the Incheon-based manufacturer said it will launch an all-cash Swiss tender for peptide CDMO PolyPeptide Group at CHF 44.31 a share, implying about CHF 1.46 billion of equity value and a path to close by year-end if conditions clear.
Contents11 sections
Key Takeaways
- Offer price is CHF 44.31 per share (~CHF 1.46 billion equity value), with tender launch targeted by end-August 2026.
- PolyPeptide’s largest shareholder (~55.65%) irrevocably committed to tender; independent board members unanimously recommend acceptance.
- Minimum acceptance is 66⅔% fully diluted; Samsung Biologics aims to squeeze out minorities and delist PolyPeptide from SIX after success.
- The deal extends Samsung Biologics beyond antibodies/ADCs into peptide APIs, including GLP-1-linked manufacturing demand.
Samsung–PolyPeptide deal at a glance
| Field | Detail |
|---|---|
| Buyer | Samsung Biologics (KRX: 207940.KS), Incheon, South Korea |
| Target | PolyPeptide Group AG (SIX: PPGN), peptide API CDMO |
| Offer price | CHF 44.31 cash per share (~CHF 1.46B equity value) |
| Premiums (per wire) | 40% vs CHF 31.65 undisturbed close (10 Apr 2026); ~11.6% vs 60-day VWAP |
| Support | ~55.65% largest-shareholder tender undertaking; board recommendation |
| Timing | Prospectus by end-Aug 2026; completion targeted end-2026 |
| Strategic aim | Multi-modality CDMO (antibodies/ADCs + peptides) + global site network |
What did Samsung Biologics announce on 19 July 2026?
According to Samsung Biologics’ 19 July 2026 PR Newswire release, the company will launch an all-cash public tender for 100% of PolyPeptide’s fully diluted share capital (excluding treasury shares) at CHF 44.31 per share.
That price implies about CHF 1.46 billion of equity value. Samsung Biologics said completion is expected toward the end of 2026, subject to a 66⅔% minimum acceptance threshold, regulatory approvals, and other Swiss takeover conditions. The formal prospectus is expected by the end of August 2026, followed by a cooling-off period and an offer open for at least twenty SIX trading days.
Reuters’ 20 July 2026 report on the $1.8 billion all-cash bid framed the same economics for global markets and underscored that PolyPeptide would become a wholly owned Samsung Biologics subsidiary if the squeeze-out and delisting path proceeds after a successful offer.
How strong is shareholder and board support?
Samsung Biologics’ wire states that PolyPeptide’s board, acting through independent and non-conflicted members, unanimously recommends that shareholders accept the offer subject to prospectus terms. The largest shareholder, holding about 55.65% of outstanding shares excluding treasury shares, gave an irrevocable undertaking to tender all of its shares.
That support does not waive the two-thirds acceptance condition. Investors should still watch Swiss takeover mechanics, regulatory clearances, and whether remaining float tenders in sufficient volume. Until the prospectus publishes, detailed offer conditions and regulatory lists remain those described in the pre-announcement referenced in the July wire.
Why peptides—and why now—for a Korea CDMO?
Samsung Biologics said the acquisition expands capabilities beyond antibodies and antibody-drug conjugates into peptide therapeutics, citing demand for obesity and diabetes peptides including GLP-1 therapies and broader peptide use in oncology and other indications. PolyPeptide is described as a specialized peptide-API CDMO with more than 70 years of manufacturing heritage and over 1,000 therapeutic peptides produced to date.
For APAC market watchers, the strategic signal is modality diversification from an Asia-headquartered scale CDMO rather than a pure capacity add in Songdo. Peptide manufacturing bottlenecks have been a recurring sponsor complaint in metabolic programs; buying a dedicated network is a faster path than organic build-out alone.
What manufacturing footprint would Samsung Biologics gain?
The July release says PolyPeptide operates sites across Sweden, Belgium, France, the United States, and India, plus a Swiss corporate office and an Innovation Center in Strasbourg. That footprint complements Samsung Biologics’ Korea base and its recent U.S. manufacturing move.
In Samsung Biologics’ 31 March 2026 PR Newswire on completing the Rockville, Maryland plant acquisition from GSK, the company said the site adds 60,000 liters of drug-substance capacity and lifts total global manufacturing capacity to 845,000 liters alongside Songdo. Together, Rockville plus PolyPeptide’s peptide network would give Samsung Biologics a multi-region, multi-modality story that is harder for single-site APAC peers to match quickly.
How should sponsors and investors read closing risk?
Key watch items are prospectus timing, the 66⅔% threshold, and listed regulatory approvals. Samsung Biologics said that after a successful offer it intends to pursue a squeeze-out of remaining minorities and delist PolyPeptide from SIX. Until close, PolyPeptide remains an independent SIX-listed company; customers should not assume immediate contract migration or capacity reallocation.
The July wire quotes Samsung Biologics CEO John Rim on modality expansion into peptides including GLP-1 and greater proximity in the U.S., Europe, and India. Those are strategic aims, not guaranteed volume or margin outcomes. Integration risk—quality systems, IT, customer confidentiality walls, and peptide vs mammalian manufacturing cultures—will determine whether the CHF 1.46 billion equity check buys durable CDMO share.
What does this mean for APAC biopharma deal flow?
Korea’s largest biopharma M&A package in recent coverage sets a high bar for APAC CDMO consolidation. Sponsors running dual antibody and peptide pipelines may see more one-stop RFP options if the platform integrates cleanly. Rival APAC CDMOs without peptide depth may face pressure to partner, build, or buy niche API capacity.
Related NovaPharmaNews APAC context includes the Insilico–Bora AI manufacturing alliance, our note on the drug-discovery technology market outlook, and TGA Australia approval coverage for regional regulatory timing.
What remains unproven until close?
Neither the Samsung Biologics wire nor Reuters confirms that every PolyPeptide customer contract, late-stage peptide project, or site utilization rate will transfer at current economics. Efficacy claims for any client’s peptide drug are out of scope for a CDMO M&A story. Treat CHF 44.31, the 55.65% undertaking, and end-2026 timing as disclosed offer terms—not as completed ownership—until acceptance and approvals are reported in a subsequent primary disclosure.
Frequently Asked Questions
What is Samsung Biologics offering for PolyPeptide?
Samsung Biologics is launching an all-cash public tender offer at CHF 44.31 per PolyPeptide share, implying about CHF 1.46 billion of equity value, with completion targeted toward the end of 2026 subject to offer conditions and approvals.
Why does the PolyPeptide deal matter for APAC CDMOs?
The bid would move a Korea-based biologics CDMO into peptide API manufacturing, including demand tied to obesity and diabetes peptides such as GLP-1 therapies, while adding sites in Europe, the United States, and India to an Asia-anchored network.
What could still block or delay the tender offer?
The offer needs at least two-thirds acceptance on a fully diluted basis, customary regulatory approvals, and completion of Swiss takeover steps including prospectus publication expected by the end of August 2026.
Primary Sources
This article follows our editorial standards. Report a correction via editorial contact.
